@article{Temthup_Nilmanat_Udomvisatson_Hongsakul_2022, title={Quality of Life among Hepatocellular Carcinoma Patients Received Transcatheter Arterial Chemoembolization: Longitudinal Prospective Study}, volume={9}, url={https://he02.tci-thaijo.org/index.php/apnj/article/view/255749}, abstractNote={<p>The quality of life among hepatocellular carcinoma patients received with TACE each period is different, with various factors involved both internally and externally. This descriptive research aimed to compare the quality of life among hepatocellular carcinoma  patients  received TACE  ≤ 3 times and ≥ 4 times. Data were collected at a university hospital in southern Thailand, from November 2017 to June 2019. Sixty-five hepatocellular carcinoma patients were recruited and received TACE 293 times, collecting data continuously for 6 times, before receiving initial TACE and after receiving TACE 1-5 times. Research instruments included the EORTC QLQ-C30 and HCC18. Cronbach’s alphas for the EORTC QLQ-C30 and HCC18 questionnaires were 0.79 and 0.80, respectively. Data were analyzed using paired t-test. Results show that: (1) The level of global health status of hepatocellular carcinoma patients received with TACE ≤ 3 times, ≥ 4 times were good and higher than initial receiving TACE. (2) There was no significant mean score global health status of hepatocellular carcinoma patients who received with TACE ≤ 3 times, ≥ 4 times. The results showed that TACE treatment for hepatocellular carcinoma patients can improve quality of life.</p>}, number={1}, journal={Thai Journal of Nursing and Midwifery Practice}, author={Temthup, Suthisa and Nilmanat, Kittikorn and Udomvisatson, Rungtip and Hongsakul, Keerati}, year={2022}, month={Jun.}, pages={71–87} }